CLINICAL_TRIALS
trial_result
· 2021-04-09
Clinical Trial Update: Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma [Phase 2]
Summary
Phase 2 trial of the EZH2 inhibitor tazemetostat in mesothelioma with BAP1 loss of function has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Epizyme, Inc. | Conditions: Mesothelioma, BAP1 Loss of Function | Phase 2 | Status: COMPLETED | Results posted: 2021-04-09